Drug Shortage Report for ZEPZELCA
| Report ID | 234751 |
| Drug Identification Number | 02520834 |
| Brand name | ZEPZELCA |
| Common or Proper name | Lurbinectedin |
| Company Name | JAZZ PHARMACEUTICALS IRELAND LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | LURBINECTEDIN |
| Strength(s) | 4MG |
| Dosage form(s) | POWDER |
| Route of administration | INTRAVENOUS |
| Packaging size | Carton containing 1 vial |
| ATC code | L01XX |
| ATC description | |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2024-11-01 |
| Actual start date | |
| Estimated end date | Unknown |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2024-11-02 |
| Company comments | This is a supply decision specific to Canada as a result of the reimbursement assessment by CADTH and INESSS. In 2023, both CADTH and INESSS issued a 'do not list' recommendation. With no available pathway in the near term for reimbursement, at this time, the company will not be able to continue maintaining supply of Zepzelca in Canada (beyond what is currently in country). |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 5TH FLOOR, WATERLOO EXCHANGE, WATERLOO RD. DUBLIN, DUBLIN IRELAND D04 E5W7 |
| Company contact information | Medical Information T: +1 800 520 5568 ; E: medinfo-ca@jazzpharma.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v10 | 2024-11-02 | English | Compare |
| v9 | 2024-09-12 | French | Compare |
| v8 | 2024-09-12 | English | Compare |
| v7 | 2024-08-15 | French | Compare |
| v6 | 2024-08-15 | English | Compare |
| v5 | 2024-08-13 | French | Compare |
| v4 | 2024-08-13 | English | Compare |
| v3 | 2024-08-07 | English | Compare |
| v2 | 2024-08-07 | English | Compare |
| v1 | 2024-08-07 | English | Compare |
Showing 1 to 10 of 10